“Additionally, in immunology, we are also now enrolling patients in a pivotal Phase II study for our CD19 NEX-T cell therapy in severe refractory lupus. Data readouts are expected to continue next year and throughout the end of the decade, providing an increasing line of sight into the strength of our pipeline.”

How to check this claim

Look at: Disclosure of clinical data readout(s) for the CD19 NEX-T cell therapy pivotal Phase II study in severe refractory lupus

It came true if: At least one data readout for this program is publicly disclosed (press release, conference presentation, or publication) during 2026

Where: Company press releases, quarterly earnings calls, or medical conference presentations (e.g., ACR, EULAR) referencing the CD19 NEX-T lupus program

Verify independently

SEC filings for BMY ↗ · Claim quote is verbatim from the 2025Q2 earnings call.